Sompharmaceuticals

Epalinges, Switzerland Founded: 2012 • Age: 14 yrs Acquired By Amryt Pharma
Somatostatin analogue peptides are developed for rare neuroendocrine diseases.
Request Access

About Sompharmaceuticals

Sompharmaceuticals is a company based in Epalinges (Switzerland) founded in 2012 was acquired by Amryt Pharma in April 2016.. Sompharmaceuticals has raised $851.87 thousand across 2 funding rounds from investors including Amryt Pharma. Sompharmaceuticals operates in a competitive market with competitors including Moderna, BridgeBio, Spark Therapeutics, Mereo BioPharma and Amicus Therapeutics, among others.

  • Headquarter Epalinges, Switzerland
  • Sectors
    Healthcare
  • Phone
    *********
  • Website
    *********
Operational Areas
Healthcare → Healthcare Products & Supplies
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Total Equity Funding
    $851.87 K (USD)

    in 2 rounds

  • Latest Funding Round
    $851.87 K (USD), Series A

    Apr 29, 2014

  • Investors
  • Employee Count
    Employee Count
  • Acquired by
    Amryt Pharma

    (Apr 18, 2016)

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Funding Insights of Sompharmaceuticals

Sompharmaceuticals has successfully raised a total of $851.87K across 2 strategic funding rounds. The most recent funding activity was a Series A round of $851.87 thousand completed in April 2014. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 2
  • Last Round Series A — $851,866
  • First Round

    (15 Oct 2013)

  • Investors Count
Date Amount Transaction Name Valuation Lead Investors Investors
Apr, 2014 Amount Series A - Sompharmaceuticals Valuation

investors

Oct, 2013 Amount Grant - Sompharmaceuticals Valuation

investors

Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in Sompharmaceuticals

Sompharmaceuticals has secured backing from 1 investor. Prominent investors backing the company include Amryt Pharma. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Investor Description Founded Year Domain Location
Therapeutics for rare dermatological and orphan diseases are developed.
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by Sompharmaceuticals

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - Sompharmaceuticals

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Sompharmaceuticals Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Sompharmaceuticals

Sompharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, BridgeBio, Spark Therapeutics, Mereo BioPharma and Amicus Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
mRNA-based therapeutics for diseases including cancer and infections are developed.
domain founded_year HQ Location
Therapeutics for genetic diseases are developed through targeted interventions.
domain founded_year HQ Location
Gene therapies for rare diseases including retinal dystrophies are developed.
domain founded_year HQ Location
Therapeutics for cancer and rare diseases are developed.
domain founded_year HQ Location
Developer of therapies for rare and orphan diseases
domain founded_year HQ Location
Developer of therapeutics to treat rare genetic diseases
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Sompharmaceuticals

Frequently Asked Questions about Sompharmaceuticals

When was Sompharmaceuticals founded?

Sompharmaceuticals was founded in 2012 and raised its 1st funding round 1 year after it was founded.

Where is Sompharmaceuticals located?

Sompharmaceuticals is headquartered in Epalinges, Switzerland. It is registered at Epalinges, Vaud, Switzerland.

Is Sompharmaceuticals a funded company?

Sompharmaceuticals is a funded company, having raised a total of $851.87K across 2 funding rounds to date. The company's 1st funding round was a Grant of $109.93K, raised on Oct 15, 2013.

What does Sompharmaceuticals do?

SomPharmaceuticals was founded in 2012 as a biopharmaceutical entity in Epalinges, Switzerland. Focus is placed on somatostatin analogue peptide medicines targeting rare neuroendocrine conditions, including orphan drug candidates for acromegaly and Cushings disease. Operations emphasize development for patient needs in these areas. As of May 13, 2016, the company has been operated as a subsidiary of Amryt Pharma.

Who are the top competitors of Sompharmaceuticals?

Sompharmaceuticals's top competitors include Moderna, Spark Therapeutics and BridgeBio.

Who are Sompharmaceuticals's investors?

Sompharmaceuticals has 1 investor. Key investors include Amryt Pharma.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available